

Glen A Doherty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9280828/publications.pdf>

Version: 2024-02-01

89
papers

4,632
citations

126708

33
h-index

110170

64
g-index

89
all docs

89
docs citations

89
times ranked

6363
citing authors

#	ARTICLE	IF	CITATIONS
1	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
3	Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? – The Pro Position. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 36-41.	0.8	1
4	The Trypanosoma brucei-Derived Ketoacids, Indole Pyruvate and Hydroxyphenylpyruvate, Induce HO-1 Expression and Suppress Inflammatory Responses in Human Dendritic Cells. <i>Antioxidants</i> , 2022, 11, 164.	2.2	5
5	Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [Variability in Response in IBD Against SARS-CoV-2 Immunisation]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1354-1362.	0.6	15
6	Faecal calprotectin as a potential biomarker of disease severity in SARS-CoV-2 infection. <i>Journal of Infection</i> , 2022, 85, 436-480.	1.7	2
7	Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1502.	2.4	1
8	Characteristics and attitudes of first round invitees in the Irish National Colorectal Cancer Screening Programme. <i>Frontline Gastroenterology</i> , 2021, 12, 374-379.	0.9	0
9	Dysregulation of Metabolic Pathways in Circulating Natural Killer Cells Isolated from Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1316-1325.	0.6	18
10	A case-control study examining the association of smad7 and TLR single nucleotide polymorphisms on the risk of colorectal cancer in ulcerative colitis. <i>Colorectal Disease</i> , 2021, 23, 1043-1048.	0.7	7
11	Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 956-959.	0.9	6
12	Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1684-1693.	0.9	14
13	Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1110-1123.	1.9	26
14	The effect of sedation on EGD inspection time. <i>Gastrointestinal Endoscopy</i> , 2021, 94, 875-876.	0.5	1
15	Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 674-675.	1.9	0
16	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
17	Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. <i>Journal of Molecular Medicine</i> , 2020, 98, 149-159.	1.7	2
18	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478

#	ARTICLE	IF	CITATIONS
19	UEG framework for the development of high-quality clinical guidelines. United European Gastroenterology Journal, 2020, 8, 851-864.	1.6	9
20	Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network. Ecological Management and Restoration, 2020, 33, .	0.2	13
21	Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Alimentary Pharmacology and Therapeutics, 2020, 52, 135-142.	1.9	51
22	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. Journal of Crohn's and Colitis, 2020, 14, 1503-1511.	0.6	100
23	Mucosal inflammation downregulates PHD1 expression promoting a barrier-protective HIF \pm response in ulcerative colitis patients. FASEB Journal, 2020, 34, 3732-3742.	0.2	16
24	Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction. Frontline Gastroenterology, 2020, 11, 441-447.	0.9	6
25	Simultaneous Metastases of Adenocarcinoma of the Lung to the Small and Large Intestine. ACG Case Reports Journal, 2020, 7, e00331.	0.2	0
26	KH-Type Splicing Regulatory Protein Controls Colorectal Cancer Cell Growth and Modulates the Tumor Microenvironment. American Journal of Pathology, 2019, 189, 1916-1932.	1.9	8
27	Hypoxia-inducible factor hydroxylase inhibition enhances the protective effects of cyclosporine in colitis. American Journal of Physiology - Renal Physiology, 2019, 317, G90-G97.	1.6	10
28	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. Expert Opinion on Biological Therapy, 2019, 19, 907-918.	1.4	6
29	DUBLIN [Degree of Ulcerative colitis Burden of Luminal Inflammation] Score, a Simple Method to Quantify Inflammatory Burden in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1365-1371.	0.6	20
30	Acceptance and Commitment Therapy Reduces Psychological Stress in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, 935-945.e1.	0.6	114
31	Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose) Tj ETQq1 1 0,784314 rgBT /Ove	1.1	9
32	Patient Education in Inflammatory Bowel Disease: A Patient-Centred, Mixed Methodology Study. Journal of Crohn's and Colitis, 2018, 12, 419-424.	0.6	23
33	CRP/Albumin Ratio. Journal of Clinical Gastroenterology, 2018, 52, e48-e52.	1.1	64
34	Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. Journal of Crohn's and Colitis, 2018, 12, 376-378.	0.6	50
35	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 17-31.	0.6	151
36	Vedolizumab-induced acne in inflammatory bowel disease. International Journal of Dermatology, 2018, 57, 752-753.	0.5	2

#	ARTICLE	IF	CITATIONS
37	Severe Symptomatic Primary CMV Infection in Inflammatory Bowel Disease Patients with Low Population Seroprevalence. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-5.	0.7	12
38	A prospective study of faecal immunochemical testing following polypectomy in a colorectal cancer screening population. <i>Frontline Gastroenterology</i> , 2018, 9, 295-299.	0.9	4
39	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1019-1026.	0.8	9
40	Covered self-expanding metal stents for the management of common bile duct stones. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 181-186.	0.5	35
41	Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. <i>Frontiers in Immunology</i> , 2017, 8, 86.	2.2	167
42	Enrichment of Inflammatory IL-17 and TNF- α Secreting CD4+ T Cells within Colorectal Tumors despite the Presence of Elevated CD39+ T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. <i>Frontiers in Oncology</i> , 2016, 6, 50.	1.3	26
43	Letter: Vedolizumab in Pregnancy. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw214.	0.6	7
44	Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF- κ B-dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2016, 474, 579-586.	1.0	26
45	DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 77-86.	0.6	115
46	Hypoxia-dependent regulation of inflammatory pathways in immune cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 3716-3724.	3.9	151
47	Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. <i>World Journal of Gastrointestinal Endoscopy</i> , 2016, 8, 723.	0.4	16
48	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2806-2814.	0.9	46
49	Magnetic resonance enterography findings as predictors of clinical outcome following antitumor necrosis factor treatment in small bowel Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 956-962.	0.8	11
50	Fecal Infliximab Loss. <i>Gastroenterology</i> , 2015, 149, 1989.	0.6	3
51	Estrogen Receptors and Their Implications in Colorectal Carcinogenesis. <i>Frontiers in Oncology</i> , 2015, 5, 19.	1.3	140
52	Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 243-250.	0.6	45
53	Body Image Dissatisfaction. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 353-360.	0.9	69
54	Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. <i>Biomarkers in Medicine</i> , 2015, 9, 363-375.	0.6	11

#	ARTICLE	IF	CITATIONS
55	The Stressometer: A Simple, Valid, and Responsive Measure of Psychological Stress in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 881-885.	0.6	9
56	An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 330-335.e1.	2.4	211
57	Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation. <i>World Journal of Gastroenterology</i> , 2014, 20, 3751.	1.4	176
58	Mortality in inflammatory bowel disease patients under 65 years of age. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 814-819.	0.6	7
59	The Body Image Scale. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 286-290.	0.9	37
60	The Frequencies and Clinical Implications of Mutations in 33 Kinase-Related Genes in Locally Advanced Rectal Cancer: A Pilot Study. <i>Annals of Surgical Oncology</i> , 2014, 21, 2642-2649.	0.7	19
61	Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population. <i>International Journal of Colorectal Disease</i> , 2014, 29, 799-803.	1.0	52
62	Determinants of short- and long-term survival from colorectal cancer in very elderly patients. <i>Journal of Geriatric Oncology</i> , 2014, 5, 376-383.	0.5	14
63	A survey of current practices used to maintain surgically induced remission following intestinal resection for Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1073-1079.	1.0	13
64	Prolonged avoidance of repeat surgery with endoscopic balloon dilatation of anastomotic strictures in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 474-480.	0.6	33
65	Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 150-153.	0.6	40
66	Sources of information and factual knowledge in Europeans with inflammatory bowel diseases: A cross-cultural comparison between German and Irish patients. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e331-e336.	0.6	18
67	The Short Health Scale: A valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 616-621.	0.6	29
68	Evaluation of the small bowel in inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 239-251.	1.4	6
69	Keeping the Bowel Regular. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2716-2724.	0.9	29
70	Hydroxylases as therapeutic targets in inflammatory bowel disease. <i>Laboratory Investigation</i> , 2013, 93, 378-383.	1.7	39
71	Pulmonary Natural Killer T Cells Play an Essential Role in Mediating Hyperoxic Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 48, 601-609.	1.4	33
72	The Influence of CTGF Single-Nucleotide Polymorphisms on Outcomes in Crohn's Disease. <i>Annals of Surgery</i> , 2013, 258, 767-774.	2.1	9

#	ARTICLE	IF	CITATIONS
73	Development, validation and clinical assessment of a short questionnaire to assess disease-related knowledge in inflammatory bowel disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 183-188.	0.6	17
74	Impact of magnetic resonance enterography in the management of small bowel Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 550-555.	0.8	18
75	A Comparative Study of Short- and Medium-term Outcomes Comparing Emergent Surgery and Stenting as a Bridge to Surgery in Patients With Acute Malignant Colonic Obstruction. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 433-440.	0.7	50
76	Depth-Dependent Differences in Community Structure of the Human Colonic Microbiota in Health. <i>PLoS ONE</i> , 2013, 8, e78835.	1.1	21
77	CD3 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , 2012, 42, 3062-3072.	1.6	50
78	Primary Sclerosing Cholangitis and Disease Distribution in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 439-441.	2.4	76
79	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1057-1063.	0.9	48
80	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1608-1616.	0.9	36
81	Capsule endoscopy for small-bowel evaluation in Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 167-175.	0.5	51
82	Treg CD39 expression as a modulator of intestinal inflammation in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S83.	0.9	0
83	Factors associated with patient knowledge of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S44.	0.9	0
84	Clinical and Pathological Factors Associated with Colorectal Cancer at the Upper Extreme of Life. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 794-795.	1.3	1
85	Capsule Endoscopy in Suspected Crohn's Disease: Yield Does Not Equal Diagnosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 2111.	0.2	11
86	Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. <i>BMC Cancer</i> , 2009, 9, 207.	1.1	48
87	Interventions for prevention of post-operative recurrence of Crohn's disease. <i>The Cochrane Library</i> , 2009, , CD006873.	1.5	116
88	Management of acute severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 395-405.	1.4	25
89	Expression of COX-2 and Prognostic Outcome in Uveal Melanoma. <i>Current Eye Research</i> , 2008, 33, 177-184.	0.7	20